227 Assessment of cervical cancer screening in Kazakhstan

IntroductionIn Kazakhstan, cervical cancer (CC) takes 2nd place among woman cancer and 7th place in general cancer mortality. Cytological screening in country have started in 2008. Kazakhstan plans to join the program for the global elimination of cervical cancer by introducing vaccination, improvin...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of gynecological cancer Vol. 30; no. Suppl 3; p. A94
Main Authors Kaidarova, D, Pak, R, Zhylkaidarova, A
Format Journal Article
LanguageEnglish
Published Oxford BMJ Publishing Group LTD 01.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:IntroductionIn Kazakhstan, cervical cancer (CC) takes 2nd place among woman cancer and 7th place in general cancer mortality. Cytological screening in country have started in 2008. Kazakhstan plans to join the program for the global elimination of cervical cancer by introducing vaccination, improving screening and treatment.MethodsThe analysis was carried out using the National Cancer Register (2020). The incidence and mortality in the period before the introduction of screening (2004–2007) were studied. The screening period is conditionally divided into the first stage (2008–2014) and the second stage (2015–2018).ResultsIn 2004–2007, the average annual incidence was 15.1 per 100,000 women. Indicators varied from 14.5 to 15.8 with an average annual growth ratio +1.9%. The average annual mortality rate was 7.4 per 100,000 female population fluctuating within 7.0–7.6%. After the introduction of screening, an increase in the incidence was noted with the ratio of 19.9–20.1 per 100,000 of women.The average annual incidence in the first stage of screening was 17.4% with an average annual growth rate +3.9%, whereas, the second stage showed a decrease in incidence with the average growth rate T=-1.4%, and the average annual incidence at 18.9%. Mortality in the first stage had an annual growth rate of T=+1.9%, in the second – T=-5.4%. Screening increased stage I from 41.7% to 62.5%, and pre-cancer – from 0.06% to 0.51%.ConclusionIn the first eight years of screening, an increase of incidence and mortality was noted. Further, the growth of the initial stage and pre-cancer diseases was pointed out.
ISSN:1048-891X
1525-1438
DOI:10.1136/ijgc-2020-IGCS.194